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Abstract
Background: Attention to and perception of physical sensations and somatic
states can significantly influence reporting of complaints and symptoms in the
context of clinical care and randomized trials. Although anxiety and high neu-
roticism are known to increase the frequency and severity of complaints, it is
not known if other personality dimensions or genes associated with cognitive
function or sympathetic tone can influence complaints. Genetic variation in
catechol-O-methyltransferase (COMT) is associated with anxiety, personality,
pain, and response to placebo treatment. We hypothesized that the association
of complaint reporting with personality might be modified by variation in the
COMT val158met genotype. Methods: We administered a standard 25-item
complaint survey weekly over 3-weeks to a convenience sample of 187 irritable
bowel syndrome patients enrolled in a placebo intervention trial and conducted
a repeated measures analysis. Results: We found that complaint severity rating,
our primary outcome, was negatively associated with the personality measures
of conscientiousness (b = 0.31 SE 0.11, P = 0.003) and agreeableness
(b = 0.38 SE 0.12, P = 0.002) and was positively associated with neuroticism
(b = 0.24 SE 0.09, P = 0.005) and anxiety (b = 0.48 SE 0.09, P < 0.0001). We
also found a significant interaction effect of COMT met alleles (b = 32.5 SE
14.1, P = 0.021). in patients genotyped for COMT val158met (N = 87) specifi-
cally COMT 9 conscientiousness (b = 0.73 SE 0.26, P = 0.0042) and
COMT 9 anxiety (b = 0.42 SE 0.16, P = 0.0078) interaction effects. Conclu-
sion: These findings potentially broaden our understanding of the factors
underlying clinical complaints to include the personality dimension of consci-
entiousness and its modification by COMT.
Introduction
Complaints in clinical practice are unwanted physical,
mental, or emotional symptoms (Wells and Kaptchuk
2012) associated with anxiety and neuroticism (Costa and
McCrae 1987). In randomized clinical trials (RCTs), these
same complaints can lead to nonadherence, treatment
failure, and treatment discontinuation by physicians and/
or patients (Mitsikostas et al. 2011). Genetic variation in
catechol-O-methyltransferase (COMT) has been shown to
be associated with anxiety, personality (Stein et al. 2005),
pain (Diatchenko et al., 2006) and response to placebo
treatment (Hall et al. 2012, Wendt, et al., 2014). We
hypothesized that the association of complaint reporting
with personality might be modified by variation in the
COMT val158met genotype.
The presence of complaints in the placebo arm of trials
suggests that in some cases symptoms are not solely attrib-
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utable to drug treatment, and are often independent of
healthcare provider treatment and RCT enrollment (Re-
idenberg and Lowenthal 1968). In RCTs, factors that con-
tribute to the reporting of these complaints include
increased awareness of and attention to preexisting condi-
tions, somatization of expected drug side effects which are
often associated with disclosures during informed consent
(Wells and Kaptchuk 2012) and the elicitation of symp-
toms as part of the data collection process, worsening of
disease, mild exacerbation of subjective symptoms (e.g.,
fatigue), emotional symptoms (e.g., anxiety) (Barsky et al.
2002; Rief et al. 2006; Amanzio et al. 2009), and psycho-
logical characteristics such as anxiety and the personality
dimension of neuroticism (Costa and McCrae 1987). The
tendency to somaticize has been associated with tempera-
ment in some studies (Hyphantis et al. 2013) but not in
others (Karvonen et al. 2006), and symptom reporting is
in turn influenced by affective states even in the absence
of a difference in symptom severity (Skotzko 2009).
Although the total system that gives rise to symptom com-
plaints is not fully understood, personality may play a
broad role, either by altering symptom severity, symptom
perception, or desire to report.
This network of affective, personality, and cognitive
states is rendered more complex by potential genetic vari-
ation in genes such as COMT which is involved in medi-
ating sympathetic and dopaminergic tone through the
catecholamine pathway. COMT degrades catecholamines
such as dopamine, epinephrine, and norepinephrine, and
has been shown to influence anxiety and personality.
Genetic variation at the COMT val158met locus has been
extensively studied because this functional polymorphism
results in a three- to fourfold reduction in the activity of
the methionine (met) form of the enzyme as compared to
the valine (val) form and this activity is inversely corre-
lated with catecholamine levels. COMT val158met genetic
variation has also been associated with sensitivity to pain
(Diatchenko et al. 2006), cognitive and executive func-
tions (Meyer-Lindenberg et al. 2005), and response to
placebo treatment (Hall et al. 2012). Associations between
COMT genotype and personality traits have also been
reported in several studies (Stein et al. 2005; Aoki et al.
2011).
Using a convenience sample from a previously reported
irritable bowel syndrome (IBS) clinical trial (Kaptchuk
et al. 2008), we investigated psychological and genetic
correlates of complaint reporting independent of treat-
ment. IBS is a chronic condition characterized by abdom-
inal pain, bloating, and altered bowel function (Somers
and Lembo 2003). Although few patients in this trial
attributed their complaints to the study (Kaptchuk et al.
2008), placebo response was associated with COMT
val158met (Hall et al. 2012). Here, we examine the rela-
tionship between anxiety and the personality traits neu-
roticism, conscientiousness, agreeableness, extraversion,
and openness (McCrae and Costa 1987) on complaint
ratings and the interaction of these personality dimen-
sions with variation at COMT val158met.
Materials and Methods
Subjects and clinical trial design
Details of the design and outcomes of this IBS placebo
trial are provided elsewhere (Conboy et al. 2006; Kapt-
chuk et al. 2008). Briefly, the parent RCT investigated the
effects of placebo acupuncture on IBS symptoms. No
active medication was given. Enrolled patients were
≥18 years old and diagnosed by Rome II criteria for IBS
with a score of >150 on the IBS Symptom Severity Scale
(IBS-SSS), n = 262 (Francis et al. 1997). Participants were
recruited from advertisements and flyers and through
referrals from health professionals. A board-certified gas-
troenterologist confirmed the diagnosis of IBS. Patients
were excluded if they had weight loss greater than 10% of
body weight, fever, blood in stools, a family history of
colon cancer, inflammatory bowel disease, significant psy-
chiatric comorbidities, or prior acupuncture treatment.
Patients were allowed to continue taking medications for
IBS if the therapeutic regimen had remained constant for
the previous 30 days, and they agreed to keep the regi-
men constant during the trial. A subset of the patients
enrolled in the trial (N = 187) completed at least one
complaint survey over the 3-week trial period. The Insti-
tutional Review Board at Beth Israel Deaconess Medical
Center (Boston, MA) approved this study which was con-
ducted in accordance with the Declaration of Helsinki.
Self-report measures
A survey of 25 common complaints (Reidenberg and
Lowenthal 1968) was administered weekly to IBS patients
enrolled in the IBS placebo trial. Patients were asked to
rate the severity of their complaints on a scale of 1 to 5
(5 being the most severe) and to indicate whether they
attributed the complaint to the study. The primary out-
come in this study, complaint severity rating, was the
sum of all the severity ratings and ranged theoretically
from 0 for no side effects to 125 for all side effects with
the maximum severity. Since this standardized index
included symptoms typically associated with IBS, such as
constipation and diarrhea, the questionnaire was modified
to ask whether the patient experienced “more constipa-
tion” or “more diarrhea.” Complaints attributed to the
placebo (sham acupuncture) intervention (i.e., side effects
perceived to be due to treatment) were reported elsewhere
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(Kaptchuk et al. 2008). Neuroticism, conscientiousness,
agreeableness, openness to experience, and extraversion
were assessed using the NEO Five-Factor Inventory
(NEO-FFI). Anxiety was measured using the Beck Anxiety
Scale (Beck et al. 1988), and somatization was assessed
using the Whitely index (Pilowsky 1967).
Genotyping
Genomic DNA was extracted from whole blood samples
from patients who gave consent for genetic analysis
(N = 112) using the Qiagen Blood Kit (Valencia, CA) fol-
lowing the manufacturer’s protocol. Eighty-seven patients
who reported complaints also consented to be genotyped.
TaqMan SNP Genotyping assay for COMT val158met
(rs4680) was purchased from Applied Biosystems (Foster
City, CA). Quantitative PCR was performed at the Bio-
polymers Facility at Harvard Medical School (Boston,
MA), following the manufacturer’s protocol on an
Applied Biosystems 7900HT instrument, using SDS ver-
sion 2.4 software.
Statistical analysis
To evaluate associations between personality, baseline
anxiety, somatization (Whitely Index), IBS-SSS, age, and
gender with the primary outcome complaint severity rat-
ing across the 3 weeks of the trial we used generalized
estimating equations (GEE) to carry out a repeated mea-
sures general linear model procedure analysis. Within-
subject correlation structure was set as exchangeable and
week number was included as a covariate. A subanalysis
of patients genotyped at COMT val158met was carried
out to examine the interaction between significant per-
sonality measures and COMT genotype, using the same
statistical parameters for personality and dividing patients
into met allele carriers or val/val homozygotes. Hardy–
Weinberg equilibrium (HWE) for genotype frequency was
calculated using the Online Encyclopedia for Genetic Epi-
demiology studies (http://www.oege.org/software/hwe-mr-
calc.shtml) (Rodriguez et al. 2009). Data were analyzed
using SAS Version 9.3 (SAS Institute Inc., Cary, NC).
Results
Most of the patients in the trial who completed the
weekly complaint survey (N = 187) were women (78%),
with an average age of approximately 39  15 years. Less
than half were married or living with a partner (43%),
and the majority were white (89% of the total sample,
and 94% of those genotyped) (Table 1). The compara-
tively higher percentage of white subjects carrying met
alleles is consistent with current estimates of global
COMT allele frequencies (Palmatier et al. 1999). Baseline
IBS symptom severity scale and psychological measures
are given in Table 1.
Although the number of respondents varied across the
3 weeks (week 1, N = 152; week 2, N = 185; and week 3,
N = 126), the responses were consistent and highly corre-
lated (Table 2). There was no significant difference in
complaint severity rating between genotyped subjects and
subjects who were not genotyped (P = 0.82). Very few
patients categorized their complaints as a study-related
side effect. The complaint most frequently attributed to
the trial placebo interventions was increased constipation
(4%). The most frequent complaint was fatigue, with over
50% of patients reporting fatigue across all 3 weeks
(Table 2). Other commonly reported complaints were
headache, irritability, inability to concentrate, and nasal
congestion. Vomiting and excessive bleeding were the
least frequently reported complaints across all 3 weeks.
In an unadjusted repeated measures model we found
that our primary outcome, complaint severity rating, was
positively associated with somatization as measured by
the Whitely Index of hypochondriasis (b = 1.81, SE 0.40,
P < 0.0001), anxiety as measured by the Beck Anxiety
Scale (b =0.48, SE 0.09, P < 0.0001), and the patient’s
baseline IBS symptom severity scale (b = 0.03, SE 0.01,
P = 0.001) (Table 3). Complaint severity rating was posi-
tively associated with the NEO Five-Factor Inventory
(NEO-FFI) personality dimensions of neuroticism
(b = 0.24, SE 0.09, P = 0.005). In addition we found that
complaint severity rating was negatively associated with
conscientiousness (b = 0.31, SE 0.11, P = 0.003) and
agreeableness (b = 0.38, SE 0.12, P = 0.002) but not
openness to experience (b = 0.08, SE 0.13, P = 0.5) or
extraversion (b = 0.16, SE 0.13, P = 0.2) (Table 3).
Since conscientiousness and agreeableness were also asso-
ciated with complaint severity rating we further examined
the correlation of these personality dimensions with neu-
roticism. We found that conscientiousness (r = 0.41,
P < 0.0001) and agreeableness (r = 0.39, P < 0.0001)
were both inversely correlated with neuroticism; conscien-
tiousness and agreeableness were also correlated with each
other (r = 0.30, P < 0.0001). Complaint severity rating
was not associated with age or gender (Table 3).
In weeks 1, 2, and 3 (N = 87, 82, 61, respectively)
patients who completed the complaint survey were also
genotyped. The distribution of patients in week 1 by
COMT rs4680 val15met (v2= 0.07, P = 0.791) was in
HWE with 21% of the patients having the met/met geno-
type, 51% val/met, and 28% val/val (Table 1). A signifi-
cant main effect of COMT met alleles (b = 32.5, SE
14.1, P = 0.0212) was qualified by COMT met
alleles 9 conscientiousness (b = 0.73, SE 0.3, P = 0.0042)
and COMT met alleles 9 anxiety interactions
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(b = 0.42, SE 0.16, P = 0.0078) (Table 4). The COMT
met allele 9 neuroticism (b = 0.27, SE 0.27, P = 0.3) and
COMT met allele 9 agreeableness interactions
(b = 0.008, SE 0.28, P = 0.9784) were not significant.
We did not correct for multiple testing, and as such the
results are hypothesis-generating and require replication.
Discussion
The findings reported here potentially broaden our
understanding of the factors that contribute to nonspe-
cific clinical complaints by including the personality
dimension of conscientiousness. As expected, we also
found that neuroticism and baseline IBS symptom sever-
ity were associated with complaints. We additionally
observed that the relationship between complaint severity
reports and personality was modified by genetic variation
in COMT.
Table 1. Demographics and baseline characteristics.
All patients (N = 187)
COMT genotyped subset (N = 82)
met/met (n = 17) val/met (n = 42) val/val (n = 23)
Demographics
Age in years, mean 39 (15) 39 (13) 37 (13) 40 (14)
Women (%) 145 (78) 14 (82) 33 (79) 18 (79)
White (%) 164 (89) 17 (100) 39 (93) 21 (91)
Married/living together (%) 69 (43) 8 (53) 15 (47) 8 (38)
IBS severity and psychological measures
Baseline IBS-SSS 278 (72) 298 (83) 263 (69) 270 (61)
Beck anxiety 12.3 (8.9) 14.3 (7.6) 13.0 (10.9) 12.3 (9.1)
Whitely somatization 2.2 (2.0) 2.6 (1.6) 1.9 (2.1) 2.5 (1.9)
Conscientiousness1 47.0 (13.6) 44.3 (13.8) 47.8 (13.3) 47.3 (13.1)
Neuroticism 52.2 (11.7) 55.7 (12.1) 51.9 (12.2) 52.2 (10.9)
Agreeableness 51.7 (12.5) 50.6 (11.8) 51.2 (13.2) 54.2 (11.0)
Extraversion 53.1 (12.1) 49.2 (13.1) 53.6 (12.5) 53.0 (10.9)
Openness 57.9 (11.4) 55.5 (11.4) 59.4 (11.1) 56.1 (10.5)
All numbers are n (SD) unless otherwise indicated.
1Five factor inventory scores are reported as T-scores.
Table 2. Mean proportion of respondents in weeks 1 (N = 152), 2
(N = 185), and 3 (N = 126) who reported each of the 25-items on
the Complain Severity Scale.
Side effect Mean among weeks SD
Fatigue 0.60 0.01
Headache 0.48 0.03
Irritability 0.48 0.03
Nasal congestion 0.44 0.06
Inability to concentrate 0.40 0.04
Excessive sleepiness 0.33 0.02
More constipation 0.32 0.05
Insomnia 0.32 0.01
Dry mouth 0.30 0.02
Bad dreams 0.29 0.02
Faint or dizzy when stand 0.29 0.03
Pain in muscles 0.28 0.02
More diarrhea 0.28 0.02
Nausea 0.28 0.03
Pain in joints 0.27 0.02
Loss of appetite 0.20 0.01
Weakness 0.18 0.04
Bruising 0.15 0.02
Palpitations 0.13 0.02
Bleeding from gums after brushing 0.13 0.02
Skin rash 0.12 0.01
Giddiness 0.10 0.03
Fever 0.09 0.02
Vomiting 0.04 0.02
Endorse excessive bleeding 0.02 0.01
Table 3. Unadjusted repeated measures analysis of main effects on
primary outcome sum complaint severity rating.
Covariate b (SE) P-value
Personality (big five)
Conscientiousness 0.31 (0.11) 0.003
Neuroticism 0.24 (0.09) 0.005
Agreeableness 0.38 (0.12) 0.002
Extraversion 0.16 (0.13) 0.199
Openness 0.08 (0.13) 0.521
Psychosocial
Anxiety (Beck) 0.48 (0.09) <0.0001
Somatization (Whitely) 1.81 (0.40) <0.0001
IBS-SSS 0.03 (0.01) 0.001
Demographics
Age 0.05 (0.06) 0.452
Gender (F) 1.87 (1.95) 0.338
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Catechol-O-methyltransferase degrades catecholamines
such as dopamine, epinephrine, and catechol estrogen
resulting in its central role in cognitive (Mattay et al.
2003), sympathetic (Stein et al. 2005), cardiovascular
(Hall et al. 2014), and endocrine networks (Kanasaki
et al. 2008). This centrality accounts for the multiplicity
of behavioral, clinical, personality, cognitive, and pain
phenotypes influenced by genetic variation in COMT.
While many studies report that COMT is associated with
neuroticism (Stein et al. 2005), we did not find that
COMT modified the association between neuroticism and
complaint reporting. One explanation for this difference
is that our subject pool consists of IBS patients with a
Rome II IBS Symptom Severity Score of greater than 150
(Kaptchuk et al. 2008) and the relationship between
COMT and neuroticism which has not been previously
reported in this population could be considerably differ-
ent than in a healthy population. Although personality
and genotype are stable traits, the significant COMT asso-
ciation with conscientiousness and decreased complaint
severity suggests a dynamic interaction between baseline
personality traits and the active perception and articula-
tion of a complaint. In this context COMT’s ability to
affect both dopamine and epinephrine regulation makes it
a potentially pivotal target in rebalancing these systems to
alleviate complaints.
Although this complaint survey gives equal weight to
the presence and severity of each symptom, the significant
association of this measure with the Whitely Index of so-
matization and the associations with anxiety and neuroti-
cism are consistent with the literature and support the
utility of the measure used here. This study is limited by
its small size (N = 187 and 82 for the genetic subanalysis)
and the homogeneity of the population studied. Since
gender has known association with NEO personality
traits, with women often scoring higher on conscientious-
ness (Costa et al. 2001) and since COMT allele frequen-
cies vary by ethnicity, the results are not readily
generalizable beyond complaint reporting in white female
IBS patients, and the detection of a gene–personality
interaction effect in such a small sample requires replica-
tion. Furthermore, as the NEO-FFI domains were origi-
nally defined by unit-weighting (Gorsuch 1983), they are
highly correlated, and interactions of multiple traits with
a gene may be a statistical artifact. Associations found
between NEO categories and the other psychosocial char-
acteristics measured in this study are also strong, particu-
larly between neuroticism and anxiety (Jylha and
Isometsa 2006) which contextualizes the multiple signifi-
cant associations found here.
The issue of when a sensation becomes a complaint is
integral to the question of what makes persons become
patients (Eisenberg 1980). Further research on the contri-
bution of individual personality and genetic composition
is warranted to account for any subset of complaints
attributable to background factors that are amplified and
can undermine treatment.
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